ASX Announcement

28 August 2026

FY26 RESULT

FY26 SUMMARY

- Momentum built across FY26 with improvement in H2 FY26 key metrics in constant currency
- Recurring revenue[1] of A$23.4M, 84% of total revenue; 88% coverage of OPEX (FY25: 80%)
- Total revenue of A$27.9M, down 17% on pcp[2] mainly due to fewer one-off capital licence deals; in line with FY26 revenue guidance
- OPEX[3] of A$26.7M, down 16% on pcp due to cost base restructuring and ongoing cost discipline; in line with FY26 OPEX guidance
- ARR Run Rate of A$23.5M at 30 June 2026, up 7.6% in constant currency vs 30 June 2025
- Operating cash flow positive for three consecutive quarters (Q2-Q4 FY26)
- Cash of A$19.9M at 30 June 2026 and no debt (FY25: A$23.1M)

Mach7 Technologies Limited ("Mach7" or the "Company") (ASX: M7T), a healthcare software company providing a broad set of enterprise imaging solutions for modern, AI-enabled healthcare environments, today provides its full year results for the year ended 30 June 2026.

Mach7 CEO and Managing Director Teri Thomas said: "FY26 was a year of deliberate reset with the second half demonstrating progress across our strategic priorities as we delivered improvement in key metrics on a constant currency basis. We transformed the business and renewed our leadership team, introducing fresh perspectives and expertise. We also expanded our product suite, restructured our cost base and revenue mix, and established a market-leading customer engagement model. These initiatives are now delivering measurable outcomes, including new customer wins, growth from our installed base and the first Flamingo deployment, positioning Mach7 for scalable growth."

FINANCIAL RESULT

FY26 revenue of A$27.9M, was 17% down on pcp due to lower one-off capital software licence revenue, a reduction in recurring revenue and lower professional services revenue. Despite significant currency headwinds, momentum improved in H2 FY26 with total revenue of A$14.3M ahead of A$13.7M in H1 FY26 reflecting growth in subscription and professional services revenue.

Recurring revenue of A$23.4M was 8% down vs pcp as growth from new and existing customers (including the go-live of the first Flamingo module implementation in record time) was more than offset by the non-renewal of Trinity Health and the ceased Veteran's Health Administration contract in H1 FY26. Recurring revenue accounted for 84% of total revenue (FY25: 75%) and coverage of operating expenditure improved to 88% from 80% in FY25, showing improved sustainability of the

[1] Recurring revenue consists of Subscription revenue and Maintenance and Support revenue recognised.
[2] Prior corresponding period (pcp)
[3] Operating expenditure (OPEX)

business.

Operating expenses of A$26.7M were A$5.1M or 16% lower on pcp reflecting the successful execution of a cost restructuring program and ongoing cost discipline. Mach7 exited FY26 with a lower cost base and a leaner, more scalable operating model.

Adjusted EBITDA of -A$0.9M (FY25: -A$0.3M) was an improvement on H1 FY26 (-A$2.3M).[4] NPATA[5] of -A$2.9M (FY25: A$0.4M) and NPAT of -A$8.9M (FY25: -A$6.2M) were lower on pcp.

Mach7's financial position remains strong with no debt and A$19.9M cash on hand at 30 June 2026 (30 June 2025: A$23.1M).

OUTLOOK

In FY26, Mach7 reset the business, transforming the cost base, protecting its recurring revenue engine and strengthening the leadership team. The Company also established an operating and product architecture for the next phase of growth.

In FY27, the focus remains firmly on execution: positive customer outcomes, new customer wins, expanding revenue from the installed base and demonstrating operating leverage.

Mach7 will maintain disciplined capital allocation, investing selectively in innovation and growth where returns are clear.

Looking ahead, the ambition is to establish Mach7 as the default orchestration platform in its category, with broader reach through partners, expansion into additional imaging use cases, increased pricing power and recognition as the safest long-term choice for customers.

FY26 INVESTOR WEBINAR

CEO Teri Thomas and Interim CFO Shawni Hadfield will host a Zoom webinar including a Q&A session with the investment community at **9:30am (AEST) today, 28 August 2026**.

Please use the link below to register for the webinar.

https://mach7t.zoom.us/webinar/register/WN_HEKwL-FpR1ylvMrHVr1PhQ

Investors can submit questions prior to the webinar to ir@mach7t.com or ask questions via the Q&A function during the webinar.

[4] Adjusted EBITDA excludes unrealised net foreign exchange movements and non-cash share-based payments expense.
[5] NPATA (Net Profit after Tax and before Amortisation) is NPAT adjusted for amortisation of acquired intangibles.

Released on authority of the Board by Teri Thomas, Managing Director and Chief Executive Officer.

For more information, contact:

Investor Relations
Françoise Debelak Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies

Mach7 Technologies (ASX: M7T) provides enterprise imaging software that helps healthcare organizations manage, access and share diagnostic imaging data across complex environments. The Mach7 platform includes a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer and an expanding suite of Flamingo modules, expanding capabilities across workflow, interoperability and data management to support a more complete view of the patient record. Together, these capabilities help healthcare organizations build a unified, longitudinal patient record that integrates diagnostic imaging with broader clinical data. Designed for interoperability and scale, Mach7 is increasingly aligned with leading cloud ecosystems such as Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI), helping customers modernize imaging infrastructure and prepare for AI-enabled clinical workflows. Mach7 serves healthcare organizations worldwide, including integrated delivery networks, national health systems and specialist imaging providers. Visit mach7t.com for more information.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.

MACH7
Independence through Innovation